November 04, 2021 08:00 AM Eastern Daylight Time
IRVINE, Calif.--(BUSINESS WIRE)--Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that Paul A. LaViolette has been appointed to its board of directors. LaViolette has over 40 years of global medical technology management experience and is currently a Managing Partner and Chief Operating Officer at SV Health Investors (SVHI), a venture and growth equity investor in healthcare.
“I look forward to helping the Vibrato team as it sets out to deliver a clinical and economic benefit to this significant patient population.”
“Paul has helped bring forward so many ground-breaking and life-changing innovations. The contributions he has made to the medical technology industry have left a profound impact,” said Juliana Elstad, CEO of Vibrato Medical. “Paul knows firsthand the challenges medical technology innovators face, and his deep understanding of healthcare and experience guiding companies of varying sizes will provide the Vibrato board with valuable insights as we look to grow our company and create a new therapy. We're very excited to have him join Vibrato.”
Elstad refers to LaViolette’s long history in medtech, including his time as Chief Operating Officer at Boston Scientific Corporation (BSC), a $10-billion-revenue medical device leader. During LaViolette’s 15 years at BSC, he served as COO, Group President, Cardiovascular, Group President, EndoSurgery, President-Cardiology and President-International. While there, he played an integral role in innovation, from integrating two dozen acquisitions to leading extensive product development programs. This experience led him to his current role with SVHI, which he joined in 2009 as a Venture Partner and in 2011 was made a Partner. LaViolette was promoted to Managing Partner in 2014 and heads the firm’s medical device investments.
“I believe the role of entrepreneurial innovation in healthcare and medtech is critical. I’m so pleased to be joining the Vibrato board and to support development of this disruptive, noninvasive therapy for advanced peripheral arterial disease,” said LaViolette. “I look forward to helping the Vibrato team as it sets out to deliver a clinical and economic benefit to this significant patient population.”
LaViolette will join current Vibrato board members Bobby Azamian, MD, PhD, Juliana Elstad, Babak Nazer, MD, and Jason Tester.
About Vibrato Medical
Vibrato Medical is a private company located in Irvine, California. The company has developed the first wearable therapeutic ultrasound device for the noninvasive, outpatient treatment of peripheral arterial disease (PAD). It is designed to promote vasodilation, collateral vessel growth and angiogenesis, and restore perfusion. Its leadership team brings deep experience in developing and commercializing medical devices and is supported by an experienced board of directors as well as recognized clinical leaders in the field of PAD. Vibrato Medical’s mission is to be the preferred therapeutic system for patients with reduced tissue perfusion.
Name: Laurel Hood
Health + Commerce